Yatsen Announces Second Quarter 2026 Financial Results

Revenue up, but losses widen sharply as margins fall at Yatsen in Q2 2026.

What the company is saying

Yatsen frames the quarter as a period of strong growth in its skincare portfolio, highlighting a 40.4% year-over-year increase in skincare brand revenues to RMB816.1 million (US$120.3 million). The company emphasizes that skincare now accounts for 71.5% of total net revenues, up from 53.5% a year ago, attributing this to robust performance from brands like Galénic, DR.WU, and Eve Lom. The release leads with revenue growth and segment mix shift, using positive language such as 'strong growth' and 'robust performance.' Losses are disclosed directly but not highlighted, with net loss and non-GAAP net loss figures presented after revenue commentary. There is no mention of forward-looking guidance or restructuring plans. The tone is factual but leans on positive segment performance to offset the negative bottom-line trend.

What the data suggests

The disclosed figures show total net revenues rising 5.1% year-over-year to RMB1.14 billion (US$168.3 million), with skincare brand revenues surging 40.4% to RMB816.1 million (US$120.3 million). Skincare now makes up 71.5% of total revenue, up from 53.5%, indicating a major portfolio shift. Despite this, gross margin declined from 78.3% to 73.9%, and net loss ballooned from RMB19.5 million to RMB90.8 million (US$13.4 million). Non-GAAP net income of RMB11.5 million in the prior year turned into a non-GAAP net loss of RMB99.4 million (US$14.7 million). The company attributes skincare growth to specific brands but does not provide brand-level financials or cost breakdowns. The data reveals that while top-line and segment growth are real, profitability is deteriorating and margin compression is significant.

Analysis

The announcement is a factual quarterly results release, with all key claims supported by disclosed numerical data. Revenue growth, especially in the skincare segment, is clearly quantified, and both GAAP and non-GAAP net losses are transparently reported. There are no forward-looking projections or aspirational statements; all claims are realised and pertain to the reported quarter. The only slightly promotional language is the attribution of growth to 'robust performance' of certain brands, but this is not paired with unsupported financial projections or exaggerated claims. The absence of profitability (net loss has widened) means the signal cannot be strong_positive, but the disclosure is complete and proportionate. No large capital outlay or long-term benefit claims are present.

Risk flags

• ●Margin compression is evident, with gross margin falling from 78.3% to 73.9%. This signals rising costs or pricing pressure, which could further erode profitability if not addressed.
• ●Net loss has widened sharply, from RMB19.5 million to RMB90.8 million (US$13.4 million), and non-GAAP net income has reversed to a loss of RMB99.4 million (US$14.7 million). Persistent or growing losses threaten cash reserves and may require future capital raising.
• ●The company attributes growth to specific brands but does not disclose brand-level profitability or cost structure. This lack of granularity makes it difficult for investors to assess the sustainability of segment growth or identify sources of margin pressure.

Bottom line

Yatsen delivered strong skincare revenue growth in Q2 2026, with the segment now dominating its portfolio at 71.5% of total sales. Despite this top-line momentum, the company’s gross margin fell and losses widened sharply, with net loss rising to RMB90.8 million (US$13.4 million) and non-GAAP net loss at RMB99.4 million (US$14.7 million). The narrative of robust brand performance is supported at the segment level but lacks brand-specific financial detail, limiting visibility into what is driving or offsetting profitability. Investors face a clear trade-off: rapid segment growth is not translating into improved margins or net income, and the cost structure remains opaque. The most important takeaway is that revenue growth alone is not solving Yatsen’s profitability problem. Further detail on costs, cash flow, and brand-level economics is needed before the investment case improves.

Announcement summary

(NYSE:YSG) Yatsen Holding Limited reported total net revenues for the second quarter of 2026 increased by 5.1% to RMB1.14 billion (US$168.3 million) from RMB1.09 billion for the prior year period. Total net revenues from Skincare Brands for the second quarter of 2026 increased by 40.4% to RMB816.1 million (US$120.3 million) from RMB581.3 million for the prior year period. As a percentage of total net revenues, total net revenues from Skincare Brands for the second quarter of 2026 were 71.5%, as compared with 53.5% for the prior year period. Gross margin for the second quarter of 2026 decreased to 73.9% from 78.3% for the prior year period. Net loss for the second quarter of 2026 was RMB90.8 million (US$13.4 million), as compared with RMB19.5 million for the prior year period. Non-GAAP net loss for the second quarter of 2026 was RMB99.4 million (US$14.7 million), as compared with non-GAAP net income of RMB11.5 million for the prior year period. The company attributed the strong growth in its skincare portfolio to the robust performance of its clinical and premium skincare brands, including Galénic, DR.WU and Eve Lom.

Disagree with this article?